Header Logo

Connection

William Towner to Viral Load

Back to Details
This is a "connection" page, showing publications William Towner has written about Viral Load.
William Towner
Connection Strength
0.944
Viral Load
  1. Effect of an Electronic Alert on Targeted HIV Testing Among High-Risk Populations. Perm J. 2018; 22:18-015.
    View in: PubMed
    Score: 0.148
  2. Examining HIV Viral Load in a Matched Cohort of HIV Positive Individuals With and Without Psoriasis. J Drugs Dermatol. 2017 Apr 01; 16(4):372-377.
    View in: PubMed
    Score: 0.141
  3. The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):321-7.
    View in: PubMed
    Score: 0.101
  4. Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy. AIDS Res Hum Retroviruses. 2012 Dec; 28(12):1630-6.
    View in: PubMed
    Score: 0.100
  5. Short-term clinical outcomes among treatment-experienced HIV-positive patients with early low level viremia. AIDS Patient Care STDS. 2012 May; 26(5):253-5.
    View in: PubMed
    Score: 0.099
  6. Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. J Acquir Immune Defic Syndr. 2010 Apr; 53(5):614-8.
    View in: PubMed
    Score: 0.087
  7. The HIV Care Cascade Measured Over Time and by Age, Sex, and Race in a Large National Integrated Care System. AIDS Patient Care STDS. 2015 Nov; 29(11):582-90.
    View in: PubMed
    Score: 0.032
  8. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015 Aug 20; 373(8):705-13.
    View in: PubMed
    Score: 0.031
  9. HIV infection and incidence of ischemic stroke. AIDS. 2014 Aug 24; 28(13):1911-9.
    View in: PubMed
    Score: 0.029
  10. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS. 2014 Apr 24; 28(7):989-97.
    View in: PubMed
    Score: 0.029
  11. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. HIV Clin Trials. 2014 Mar-Apr; 15(2):51-6.
    View in: PubMed
    Score: 0.028
  12. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 2014 Feb 01; 65(2):160-6.
    View in: PubMed
    Score: 0.028
  13. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. 2012 Nov 13; 26(17):2223-31.
    View in: PubMed
    Score: 0.026
  14. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2551-9.
    View in: PubMed
    Score: 0.024
  15. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010; 15(7):1045-52.
    View in: PubMed
    Score: 0.021
  16. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 Jul 07; 370(9581):39-48.
    View in: PubMed
    Score: 0.018

© 2024 Kaiser Permanente